Investigational drug · Phase 3
GS101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Atopic Dermatitis (AD).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "GS101"
First trial start
2026
Jan 29, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GS101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis (AD)
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "GS101" as an intervention, largest first.
- A Phase III Study of GS101 Injection to Dupixent®Pivotal-lookingRecruiting
Jiangsu Genscend Biopharmaceutical Co., LtdIndustry
NCT07386743 · 572 participants (planned) · Start Jan 29, 2026 · Primary completion Apr 2027
Drug: GS101 injection; DUPIXENT® · For: Atopic Dermatitis (AD)
Sites: Shenyang, China
- Trial of Aganirsen in iCRVO Patients at Risk of Developing NVGPivotal-lookingStatus unknown
Gene Signal SASIndustry
NCT02947867 · 333 participants (planned) · Start Jan 2017 · Primary completion Jun 2019
Drug: aganirsen · For: Ischaemic Central Retinal Vein Occlusion; Neovascular Glaucoma
- A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous InjectionPivotal-lookingCompleted
Jiangsu Genscend Biopharmaceutical Co., LtdIndustry
NCT07411755 · 294 participants · Start Mar 5, 2026 · Primary completion Aug 8, 2026
Drug: GS101 injection; U.S. commercial Dupixent® and 1 more · For: Atopic Dermatitis (AD)
Sites: Suzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- In-depth characterization of phytase-producing plant growth promotion bacteria isolated in alpine grassland of Qinghai-Tibetan Plateau.
Li Q, Yang X, Li J, et al. · Front Microbiol 2022
- Blockade of insulin receptor substrate-1 inhibits biological behavior of choroidal endothelial cells.
Qian YY, Wu HY, Liu GQ, et al. · Int J Ophthalmol 2019
- Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
Shah A, Mangaonkar A · Ann Pharmacother 2015
- Blockade of insulin receptor substrate-1 inhibits corneal lymphangiogenesis.
Hos D, Regenfuss B, Bock F, et al. · Invest Ophthalmol Vis Sci 2011
- GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial.
Cursiefen C, Bock F, Horn FK, et al. · Ophthalmology 2009
- Tolerability and safety of GS-101 eye drops, an antisense oligonucleotide to insulin receptor substrate-1: a 'first in man' phase I investigation.
Kain H, Goldblum D, Geudelin B, et al. · Br J Clin Pharmacol 2009
Also in development for Atopic Dermatitis (AD)
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- QY201Phase 33 trials
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. · Adult Subjects With Non-Segmental Vitiligo, Atopic Dermatitis (AD), Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD)
- BFB759Phase 32 trials
Bluefin Biomedicine, Inc. · Atopic Dermatitis (AD), Hidradenitis Suppurativa (HS)
- MH004Phase 32 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Vitiligo, Atopic Dermatitis (AD)
- ENV-294Phase 23 trials
Enveda Therapeutics · Atopic Dermatitis (AD), Atopic Dermatitis, Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.